ACADIA Pharmaceuticals (ACAD) Gets 'Sell' Rating on Weak Trial Results, Shares Fall 13%
ACADIA Pharmaceuticals (NASDAQ:ACAD) fell for a fifth consecutive day on Thursday, shedding 12.78 percent to close at $22.18 apiece, after earning a sell recommendation from Goldman Sachs.








